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Abstract
The presence of certain autoantibodies in the serum of patients facilitates the diagnosis of 
particular autoimmune diseases. Some antibodies may also be significant for the progno-
sis of the disease development and internal organs involvement. In the case of Sjögren’s 
syndrome, it is known that overactivity of B-lymphocytes leads to the production of a 
number of autoantibodies—both markers for pSS (such as antibodies to ribonucleopro-
teins) and nonspecific antibodies (such as rheumatoid factor). The range of autoantibod-
ies found in pSS is constantly expanding, but their significance is not fully established. 
At present, only anti-SS-A antibodies are introduced to the criteria for the pSS diagnosis. 
However, this does not stop an interest in other autoantibodies and the significance of 
their presence for the course of this disease. This chapter outlines the autoantibodies 
found in pSS and discusses their importance in clinical practice.
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1. Introduction
Primary Sjögren’s syndrome (pSS) is a chronic, persistent autoimmune disease with predomi-
nant B cells hyperreactivity and with the production of autoantibodies against intracellular 
antigens. Autoimmune process taking place in pSS affects exocrine glands primarily, causing 
their dysfunction and the development of symptoms of mouth and eye dryness. Through the 
formation of infiltrates consisting of different autoreactive cells (e.g., B and T cells, macro-
phages, and dendritic cells), pSS may affect other organs as well as whole systems (e.g., lungs, 
respiratory, urinary, and alimentary tract).
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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1.1. Triggering factors
In the pathogenesis of primary Sjögren’s syndrome, certain genetic factors play a significant 
role, such as the presence of HLA-B8, HLA-DW3, HLA-DR3, and DRw52 genes or interferon 
regulatory factor 5 (IRF 5) gene polymorphism [1, 2]. Not only viral infections have been 
recognized as the pSS triggering factors, mainly Epstein-Barr virus (EBV) [3], but also human 
T-cell lymphotropic virus type-1 (HTLV-1), cytomegalovirus (CMV), and hepatitis C virus 
(HCV) [4, 5]. Bacterial infections Staphylococcus aureus, Chlamydia pneumoniae, Chlamydia tra-
chomatis, M. hominis, U. urealyticum, and H. pylori may also play part in the development of 
pSS [6–8]. In many of the autoimmune rheumatic diseases, ultraviolet (UV) radiation is a rec-
ognized factor influencing the activity of the autoimmune process. The UV radiation causes 
movement of antigen molecules, bound with/to ribonucleoprotein, between cytoplasm and 
cell membrane (SS-A/Ro) and cell nucleus and cytoplasm (SS-B/La). UVB radiation affects 
epithelial damage, activates plasma dendritic cells, and increases the risk of their apoptosis 
and (risk?) of the IFN signaling pathway activation. Different observations concerning UVA 
radiation suggest that it inhibits the production of autoantibodies [9, 10].
The hormonal state of the individual may also play a role in the pSS development. The imbal-
ance of sex hormones and its receptors, dependent on hypothalamic-pituitary-adrenal axis 
(HPA or HTPA axis), interferes with the ratio of estrogens to androgens, especially in geneti-
cally predisposed patients [11]. This influences the stimulation of the autoimmune process 
and may explain the more frequent occurrence of pSS in women, especially in middle-aged. 
In recent years, attention has been paid to the role of the deficiency of dehydroepiandros-
terone (DHEA) and of DHEA-S, its metabolite, in pSS and other autoimmune diseases [12].
1.2. Outline of pathogenesis
As the epithelial cell damage and apoptosis provide basis for the pSS pathogenesis, the first 
step of the whole process is the activation of innate immunity, as the virus or bacteria antigen 
activates pattern recognition receptors (PRR) via Toll-like receptors (especially TLR 3, 7, 9). 
Activation of innate immunity leads, in turn, to the damage of epithelial cells, their apoptosis 
and the release of antigens and RNA complexes that strongly stimulate plasmacytoid den-
dritic cells (pDCs). These produce interferon alpha (IFN-α)—a factor strongly stimulating epi-
thelial cells, dendritic cells and neutrophils to produce B-cell activating factor (BAFF) [13–16]. 
All processes initiating epithelial damage lead to the apoptosis of cells, activation of congeni-
tal and acquired immune systems and the cascade effect of pathophysiological phenomena, 
resulting primarily in the overproduction of BAFF and other B-cell stimulating cytokines 
including APRIL (proliferation inducing ligand), similar in its actions to BAFF. Both BAFF and 
APRIL belong to the tumor necrosis factor superfamily (TNF) [17, 18]. The antigens released 
from damaged cells, primarily SS-A and SS-B ribonucleoproteins are targets for B cells and 
cause the production of specific anti-SS-A/Ro and anti-SS-B/La autoantibodies. Plasmocytoid 
dendritic cells also stimulate T lymphocytes, particularly the CD4+ subtype, which is later the 
main component of infiltrates in the endocrine glands. The Th1-type immune response is pre-
dominant, with activation of Th17 cells secreting interleukin 17 (IL-17). Th1 cells produce IFN-
γ, which, in addition to the increase of BAFF secretion, induces the production of plasminogen 
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activator, which—simultaneously with IL-17—causes the development of local inflammatory 
process. As a result of the abovementioned changes, leading to the hyperstimulation of B lym-
phocytes, autotolerance is disturbed and further production of autoantibodies [19].
2. Autoantibodies in primary Sjögren’s syndrome
2.1. Antinuclear antibodies
A primary test for autoantibodies, finding the use in the diagnostics of pSS and other sys-
temic autoimmune rheumatic diseases (SARD), is the determination of anti-nuclear antibodies 
(ANAs) [20, 21]. ANA are found in 80–90% of patients with pSS. These antibodies react with 
the components of the cell nucleus and are most often tested with indirect immunofluores-
cence (IF) on HEp-2 (human epithelial cell) cell line. In pSS, ANA often occur in higher titers 
(above 1:320), but may be also detected in lower titers (1:160) and in the concurrent presence of 
other autoantibodies. In Table 1, the prevalence of ANA antibodies in different autoimmune 
diseases was presented.
In recent years attention has been paid to the frequent occurrence of dense fine speckled pat-
tern (DFS70) on HEp-2 in both healthy people and patients with ANA associated autoimmune 
rheumatic diseases (AARD). DFS70 antibodies bind a ubiquitinated protein called lens epithe-
lium derived growth factor (LEDGF), which occurrence was associated in first observations 
[22] with asthma and atopic dermatitis. However, the high prevalence of DFS70 autoantibod-
ies in normal population, without any symptoms of any AARD, was observed. Therefore, in 
the case of positive result of the screening for ANA antibodies in individuals without symp-
toms suggestive of a systemic autoimmune rheumatic disease (SARD/AARD), it is advisable 
to detect DFS70 antibodies using specific tests (e.g., ELISA/EIA; CLIA/CIA) [23, 24]. Even up 
to 1/3 of positive cases for ANA are also positive for DFS70 antibodies [23, 24].
2.2. Extractable nuclear antigens
In 1959, Holman et al. recorded a reaction of sera from SLE patients with extractable nuclear 
antigens (ENA) isolated from a crushed calf thymus. This observation confirmed the reaction 
of autoantibodies in the SLE sera with soluble nuclear antigens. The nomenclature of ENA 
autoantibodies derived from the group, in which they were first described, and corresponds 
to the nuclear function of the antigen (RNP) or the name of the patient providing the proto-
type serum (Ro, La, Sm, Jo, Mi), as well as the disease from which the patient suffered (SSA, 
Disease SLE SSc pSS MCTD
ANA sensitivity% 95 70–90 50–80 90
SLE—systemic lupus erythematosus; SS, SSc—systemic sclerosis, pSS—primary Sjögren’s syndrome, MCTD—mixed 
connective tissue disease.
Table 1. Prevalence of ANA antibodies in different autoimmune diseases [20, 21].
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SSB, SSC, Scl-70, PM-1, PM-Scl) [23]. The set of all ENA includes more than 100 soluble and 
cytoplasmic antigens. In clinical practice, until present day, only few of the them are finding 
use as a immunological hallmarks of certain autoimmune diseases or being used as immuno-
logical prognostic factors. Among them the most prominent are as follows: anti-RNP (anti-
ribonucleoprotein anti-U(1)RNP), anti-Sm RNP, anti-SSA/Ro, anti-SSB/La, anti-Sm (Smith) 
antibody, anti-Scl-70 (anti-topoisomerase antibodies), anti-Jo-1 (anti-histidyl-transfer RNA 
synthase antibodies). The pattern of positive and negative results obtained with an ENA 
panel should be evaluated in conjunction with all clinical findings. Main autoantibodies and 
disease which they are typical to are presented in Table 2. Selected autoimmune diseases 
along with their predominant autoantibodies are presented in Table 2. Figure 1 shows a 
simplified diagnostic algorithm of immunological diagnosis.
2.3. Characteristics of ENA antibodies and their connection with primary Sjögren’s 
syndrome
From 1981, it is known [26] that SS-A/Ro antigens are associated with small cytoplasmic RNAs. 
In 1984 Ro60 kD protein was discovered and Ben-Chetrit et al. in 1988 demonstrated second 
part of SS-A/Ro complex—a 52 kD protein [25–27]. As we have recently learned, the SS-A/
Ro antigen consists of two different proteins Ro60 and Ro 52, with different gene localiza-
tion: Ro60 is located on chromosome 19, while Ro-52 on chromosome 11. It was also revealed 
that these antigens, in physiological conditions, are found in different cell compartments. The 
detection of their presence determines different clinical implications. Presently, this problem 
needs still further investigation.
SS-A/Ro (60KD + 52KD) is a complex present on most cells, including platelets and red blood 
cells. It is considered that the anti-SS-A antibody plays a pathogenic role in pSS and its pres-
ence is associated with more severe symptoms, resulting from the involvement of endocrine 
glands, lymphadenopathy, larger salivary glandular infiltrates, characteristic vasculitis and 
longer duration of the disease [28, 29]. Also the occurrence of interstitial lung disease (ILD) is 
Disease. RA pSS MCTD SLE dSSc lSSc PM DM GPA MPA
Antibodies ACPA
RF
Anti-
SS-A/
Ro60
Anti-
SS-A/
Ro52
Anti-
SS-B/
LA
RF
RNP
RF
Anti-
dsDNA
Anti-Sm
Anti-Ro60
Anti-
Scl-70
Anti-
CENP-
A,B,C
Anti-Jo-1
Ro-52
Other anti-
synthetase 
antibodies, 
Anti-Mi-2
Anti-SRP
Anti-Ro-52
Anti-Mi-2
cANCA pANCA
RA—rheumatoid arthritis; pSS—primary Sjogren’s syndrome; MCTD—mixed connective tissue disese; SLE—systemic 
lupus erythematosus; dSSc—disseminated systemic sclerosis, lSSc-localized systemic sclerosis; PM—polymyositis; 
DM—dermatomyosistis; GPA—granulomatosis with polyangiitis; MPA—microscopic polyangiitis.
Table 2. Autoimmune diseases and main autoantibodies [20–24].
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associated with the presence of antibodies against SS-A/Ro antigens, primarily Ro52KD and 
is associated with a higher degree of inflammatory changes in the salivary glands.
The formation of anti-SS-A is affected by the UV radiation, which increases the expression 
of antigens on the cell surface. Anti-SS-A/Ro antibodies are considered as a triggering fac-
tor for photosensitivity in SCLE and NLE, although patients with DLE, but without anti-Ro 
antibodies, present skin changes after sun/light exposition as well, probably due to other 
pathomechanism (the presence of autoantibodies/immunoglobulins between skin and the 
epidermis) [30].
Ro60 antigen attaches to uncoded RNA to form a complex (hY-RNA) that plays a role in inhib-
iting the immune response. Ro52 antigen is a phosphoprotein forming due to stimulation by 
viral infection, type I interferon pathway and through Toll-like receptors [28].
2.3.1. Anti-SSA/Ro antibodies
Autoantibody Ro60 has been associated with Sjögren’s syndrome in particular but also occur 
in SLE (50%), and subacute cutaneous lupus (SCLE) (60%) and neonatal lupus (NLE) [31]. 
Anti-Ro antibodies in SLE and SCLE are associated with photosensivity and skin changes 
(SCLE, NLE). In SCLE, negative results for ANA screening or finding ANA in low titer do 
not exclude the presence of anti-SSA/Ro antibodies (antibody—negative SCLE). Anti-SS-A 
antibodies are also found in systemic sclerosis, RA and polymyositis, as well as dermatomyo-
sitis (PM/DM) and autoimmune hepatitis, with antibodies to the Ro52 antigen present more 
frequently. Anti-Ro52 antibodies frequently occur in association with anti-Ro60 antibodies, 
Figure 1. Simplified algorithm of immunological diagnosis of rheumatic diseases [22–24]. ANA—antinuclear antibodies; 
DFS70—dense fine speckled pattern antibodies; ENAs—extractable nuclear antigens; dsDNA—anti-double stranded 
DNA antibodies.
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especially in the context of SLE, Sjögren’s syndrome, subacute cutaneous lupus and neonatal 
lupus congenital heart block [31, 32]. However, the presence of anti-Ro52 alone, without anti-
Ro60, was reported in inflammatory myopathy and in systemic sclerosis. It was also observed, 
that anti-Ro52 antibodies are, to larger extent than anti-Ro60, associated with primary biliary 
cirrhosis (PBC) and autoimmune hepatitis (AIH) with co-expression of anti SLA antibodies 
(soluble liver antibodies) [33].
2.3.2. Anti-SS-B/La antibodies
Anti-SS-B/La antibodies are less common and usually coexist with anti-SS-A antibodies, and 
their presence in other systemic diseases, especially in SLE (25% of patients with TRU), is 
associated with skin lesions (erythema, alopecia), inflammation of the serous membranes, 
leukopenia, symptoms of dryness and they often coexist with the presence of anti-SS-A anti-
bodies (secondary SS) [28]. Rao et al. have noted that anti-SSB antibodies are important for 
the SLE diagnosis. They are associated with cheek erythema, alopecia, serositis, secondary 
Sjögren’s syndrome, and hematological changes such as leukocytopenia, thrombocytopenia, 
and immunoglobulins elevation. They are often accompanied by the presence of anti-/Ro 
or anti-SSA/Ro52 antibodies [34]. These autoantibodies may also be found before the SLE-
specific antibodies can be detected [35].
3. Rheumatoid factor
Rheumatoid factor (RF) is an autoantibody directed against the CH2 and CH3 domains of an 
Fc region of a class G immunoglobulin (IgG). RF is produced by plasmatic cells (RF-PCs) that 
are formed from B cells activated both dependently and independently of T lymphocytes. Thus, 
RF producing B cells (RF-PC) become cells with ability of antigen presentation (APC) and of 
binding IgG. As this cascade of events constitutes a method of immune response against the 
infectious antigens, the RF production during infections protects the host organism. This phe-
nomenon explains the occurrence of RF in the course of many viral (e.g., HCV, Herpes virus, 
and HIV), bacterial (e.g., subacute bacterial endocarditis, Chlamydia pneumoniae, Klebsiella pneu-
moniae, tuberculosis, and syphilis) and even parasitic (malaria, onchocerciasis, and toxoplasmo-
sis) infections. In those autoimmune diseases, in which B-cell hyperactivity occurs, rheumatoid 
factors, particularly clinically relevant RF-IgM, also appears [36]. It should be remembered that 
RF appears in 4% of a healthy population and its incidence increases with age; after 75 years of 
life, RF can be observed even in 10–25% of individuals [37, 38]. The frequency (%) of RF in vari-
ous CTD is presented in Table 3. The primary Sjögren’s syndrome is one of the autoimmune 
diseases in which the majority of patients have a rheumatoid factor (some authors report up 
from 60 to 90% of patients)—specifically its most common IgM class isotype. The presence of 
RF IgM is associated with the occurrence of leukopenia, increased erythrocyte sedimentation 
rate (ESR), higher concentration of gamma globulins and lower C4 complement component 
concentration. Observations of a positive correlation of the rheumatoid factor with symptoms 
of dryness, hypergammaglobulinemia, presence of higher ANA antibody titers, presence of 
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anti-SS-A antibodies, anti-SS-B, increased ESR and leukopenia were presented in their work 
by Witte et al. [39]. The presence of RF in patients with pSS, as well as in other autoimmune 
diseases, and in acute infections, indicates the formation of a large number of other antibodies 
and the formation of antigen complexes with antibodies. The frequency of RF in various CTD 
was presented in Table 3 [39].
4. Other autoantibodies
4.1. Anti-centromere autoantibodies
Anti-centromere antibodies (ACA) are directed to six antigens associated with centromere 
(composed of a complex of kinetochore proteins). Currently identified anti-centromere anti-
bodies (CENP) have been assigned designations with letters from A to F. The most common 
are CENP-A, B and C. CENP-B is also the most frequently occurring anti-centromere anti-
body in patients with pSS. The incidence of ACA antibody described in the literature ranges 
from 3.7 to 4% [40, 41]. This antibody, with a mass of 80 kDa, is a DNA-binding protein 
involved in the heterochromatin folding. Anti-centromere antibodies (A, B, C) occur mainly 
in limited systemic sclerosis (LSSc) and are associated with the prevalence of telangiectasia, 
higher severity of Raynaud’s symptom, lung involvement such as interstitial lung disease 
[ILD] and fibrosis [42]. Their relationship between the presence of ACA antibodies and the 
involvement of endocrine glands has been demonstrated; in the ACA+ group, anti-SS-A and 
anti-SS-B autoantibodies were less frequent [42].
The association of ACA antibodies with non-Hodgkin’s lymphomas (CENP-F) including 
MALT lymphomas was also described [43], as well as the case reports of CENP-B presence in 
small-cell lung cancer [44].
Interestingly, it has also been demonstrated that the presence of anti-CENP-B antibodies is 
associated with prolonged survival in a breast cancer [45].
Autoimmune connective tissue disease RF frequency%
Primary Sjögren’s syndrome 75–90
Rheumatoid arthritis 70–90
Mixed connective tissue disease 50–60
Systemic sclerosis 20–30
Systemic lupus erythematosus 15–20
Dermato/polymyositis 20
Vasculitis (GPA and MPA) 5–20
Other CTD* as psoriatic arthritis, juvenile idiopathic arthritis, and reactive arthritis 5 and <5
Table 3. The frequency of RF in various connective tissue diseases [39].
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4.2. Antibodies against citrullinated proteins
Citrullination is the post-translational process in proteins of deamination/conversion of the 
amino acids: arginine into citrulline. ACPA positive sera include antibodies to citrullinated 
proteins, such as fibrin and fibrinogen, vimentine (MCV—mutated citrullinated vimentine) 
and alpha-enolase (CEP-1).
It is known that arthritis may be one of the clinical symptoms of pSS. However, most of 
the pSS patients suffer from arthralgia, and only minority develop non-destructive arthritis. 
ACPA antibodies, a main marker of rheumatoid arthritis, are usually present in low concen-
trations in pSS according to various studies they are present in 3–22% of cases [46]. A higher 
incidence of arthritis was found in pSS patients with ACPA presence compared to patients 
without these antibodies [47]. It seems, however, that patients with pSS and ACPA positive 
require further observation toward the development of rheumatoid arthritis [48].
It should also be remembered that smoking and periodontal infection by Porphyromonas gin-
givalis are strong environmental factors stimulating protein citrullination and the emergence 
of ACPA antibodies [49].
4.3. Citrullinated alpha-enolase
Citrullinated alpha enolase (CEP-1) is an antigenic target for antibodies against citrullinated 
proteins (ACPA). In the Nezos et al. study [50], it was shown that CEP-1 antigen is a major 
antigen target in the ACPA positive subgroup of patients with pSS. The frequency of CEP-1 
antibody in the RA ACPA positive group was not as high, while it was not found healthy 
group at all. The authors drew attention to the link of anti-CEP-1 antibodies presence to 
arthritis as well as to renal tubular dysfunction.
4.4. Antibodies recognizing salivary gland and lacrimal gland tissue
In recent years, researchers identified autoantibodies to carbonic anhydrase 6 (anti-CA6 anti-
bodies), anti salivary gland protein 1 (SP-1) and anti-parotid secretory protein (PSP) [51]. 
These antibodies may emerge before pSS marker antibodies such as SS-A/Ro or SS-B/La and 
are associated with a minor focus score; these antibodies also occur more often in patients 
who did not have anti-SS-A/Ro antibodies [52]. Interestingly, in Langhe et al. work, anti CA6-
IgA antibodies were detected primarily in patients with long pSS duration; other autoanti-
bodies such as anti-CA6, PSP, and SP1 in IgG and IgM class were more frequently observed 
in SSc and MCTD with secondary SS. These autoantibodies do not allow distinguishing 
SLE from secondary SS. However, the described study was limited by a small group of SLE 
patients [52]. In the literature, some cases have been reported of patients with severe symp-
toms of eye or mouth dryness, in which there was no SS-A/Ro antibodies, but the presence 
of anti SP-1 antibody was confirmed [53]. It may suggest, that in case of a patients presenting 
unexplained dryness with no serology markers defined in current criteria for pSS, perform-
ing the test for novel, early antibodies to Sp1 and PSP may still be useful for diagnosing 
patient’s condition [53].
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4.5. Anti-muscarinic antibodies
Muscarinic 3 receptor (M3R) is found in various places in the body, such as smooth muscles, 
the endocrine and the exocrine glands, lungs, pancreas and even the brain. This receptor is 
also expressed on pancreatic beta cells, modulating insulin secretion. Activation of the M3R 
receptor induces smooth muscle constriction and increase glandular secretions [54].
It has been demonstrated that muscarinic acetylcholine type 3 receptor (M3R) antibodies 
are present in the serum of patients with pSS [54]. As it was presented by Kovacs et al., M3R 
antibodies are found in up to 90% of subjects with pSS [55]. In the group with M3R antibod-
ies, leucopenia was more frequently observed [55]. Immune response to muscarinic receptor 
3 plays a role in the pathogenesis of autoimmune sialoadenitis [56] and diabetes mellitus 
type 2. MR3 antibodies may be present in other autoimmune diseases and do not allow for 
differentiation between primary and secondary Sjögren’s syndrome. The severity of symp-
toms of dryness or dysfunction of the exocrine system in pSS may be related not only to 
MR3 antibodies presence but also to other autoantibodies such as, for example, antibodies 
to aquaporins [57].
4.6. Autoantibodies to aquaporins
Aquaporins (AQP; water channels) are integral membrane proteins that form pores in 
the membrane of biological cells, enabling transport of water between cells. Some genetic 
defects of aquaporin genes have been associated with diseases as neuromyelitis optica 
(Devic’s syndrome) and nephrogenic diabetes insipidus. First, aquaporin—“aquaporin-1” 
was described in 1992 by Peter Agre, until today we know 13 aquaporins, of which four are 
best defined [58]. Because of their influence of water transport, aquaporins have an impact 
on saliva and tear production and changes in AQP expression may lead to dryness symp-
toms [59, 60]. Aquaporin-4 (AQP4) is found on perivascular and ependymal cells, but it has 
also been discovered in sera of patients with NMO and multiple sclerosis. Tzartos and his 
colleagues detected aquaporin antibodies (AQP-1, -3, -8, and -9) in pSS patients sera [61]. 
What is interesting in the pSS group, AQP-4 and AQP-5 antibodies were not present. The 
presence of AQP antibodies was associated with more severe xeropthalmia; the authors 
suggest potential role of AQ P-Ab in salivary gland secretions. Such hypothesis requires 
further research.
4.7. Autoantibodies binding to stathmin-4
Stathmins (STMN) are phosphoproteins which play a role in neuronal development and inter-
act with tubulin. Presently, four stathmins have been identified. Stathmins are upregulated 
in a number of cancers and neuropathies [62]. Anti-stathmin-4 antibodies in IgG3 class were 
proposed as a biomarker of polyneuropathy and such observations were presented by Duda 
et al. in their study. The authors described anti-STMN4 antibodies in 33% of pSS patients 
with polyneuropathy (PNP)—vs. 7% of those without PNP—and in 45% of individuals with 
vasculitis skin changes (as opposed to 13% in individuals without them) [63].
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4.8. Anti-alpha-fodrin antibodies
Alpha fodrin is an actin-binding, organ-specific protein of the cytoskeleton. Antibodies against 
alpha-fodrin are detected in serum samples from patients with primary or secondary Sjögren’s 
syndrome especially with sicca symptoms. Some authors suggest that they can be detected 
earlier in the course of pSS, sometimes before the emergence of anti SS-A or SS-B antibodies 
[64]. These antibodies, in the IgA and IgG class of immunoglobulins, are found in the serum 
and salivary glands of patients with pSS. However, other researchers did not describe any 
significant sensitivity and specificity of these antibodies [65–67].
4.9. Autoantibodies in saliva that may be relevant in pSS associated with the 
development of MALT lymphoma
Major salivary glands are the main extra endocrine glands targeted in pSS and saliva of 
patients with pSS is also a source of antibodies and cytokines. Large salivary glands are also 
the site for MALT lymphoma development. Investigators are interested in finding biomarkers 
in saliva, that allow for early pSS diagnosis, as well as the detection of mucosa associated lym-
phoma (MALT lymphoma). Cui et al. suggest set of three autoantibodies such as anti-cofilin-1 
antibodies, anti-alpha enolase and anti-Rho GDP dissociation inhibitor 2(RGI2) antibodies, 
which, due to high specificity and sensitivity, may play a role as such biomarkers [68].
5. Autoantibodies in course of pSS—summary
In the current pSS criteria, only anti-SS-A/Ro antibodies are taken into account as the most sen-
sitive and specific for pSS diagnosis. Still, the multisymptom picture of this rheumatic disease 
compels the search for other immunologic markers of at least equal prognostic importance.
Auto-antibody Clinical findings
Anti-Ro52 kD Interstitial lung disease
Anti-Ro60 kD Hematologic changes, photosensitivity, skin involvement, Raynaud’s phenomena, and 
dryness
Anti-SS-B/La Liver (autoimmune disease) PBC
RF Dryness, hypergammaglobulinemia, and leukopenia
ACPA Arthralgia and arthritis
Anti-CENP-B Interstitial lung disease and fibrosis
Novel autoantibodies
Anti-CA6 Dryness and renal tubular acidosis
Anti-PSP Dryness
Anti-SP1 Dryness
Anti-CEP-1 Arthritis and renal tubular dysfunction.
Table 4. Antibodies in pSS and their association with clinical manifestation.
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The occurrence of some of the identified antibodies has been associated with the specific clini-
cal features such as interstitial lung disease, increased eye dryness, increased risk of nephroli-
thiasis and tubular distal acidosis or MALT lymphomas. In Table 4, autoantibodies frequently 
occurring in pSS and their association with clinical manifestation were presented.
6. Conclusions
pSS is a still not fully understood autoimmune disease, requiring doctor’s vigilance. Even 
despite of a pSS having a mild course for a long time, there is a risk of organs and systems 
involvement. As it has been known for many years already, the risk of developing lympho-
mas is particularly increased in pSS patients compared to the healthy population. Although 
only one antibody (SS-A/Ro) has been included in the pSS diagnostic criteria, a lot of attention 
has been paid to new autoantibodies that can help clinicians in patient stratification in the 
early stages of diagnosis or may have a prognostic value.
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